These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 28664499)

  • 1. Romidepsin in Japanese patients with relapsed or refractory peripheral T-cell lymphoma: a phase I/II and pharmacokinetics study.
    Maruyama D; Tobinai K; Ogura M; Uchida T; Hatake K; Taniwaki M; Ando K; Tsukasaki K; Ishida T; Kobayashi N; Ishizawa K; Tatsumi Y; Kato K; Kiguchi T; Ikezoe T; Laille E; Ro T; Tamakoshi H; Sakurai S; Ohtsu T
    Int J Hematol; 2017 Nov; 106(5):655-665. PubMed ID: 28664499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Romidepsin treatment for relapsed or refractory peripheral and cutaneous T-cell lymphoma: Real-life data from a national multicenter observational study.
    Shimony S; Horowitz N; Ribakovsky E; Rozovski U; Avigdor A; Zloto K; Berger T; Avivi I; Perry C; Abadi U; Raanani P; Gafter-Gvili A; Gurion R
    Hematol Oncol; 2019 Dec; 37(5):569-577. PubMed ID: 31674027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Romidepsin (Istodax
    Ro T; Nakayama N; Achiwa H; Ohtsu T
    Nihon Yakurigaku Zasshi; 2018; 151(3):122-129. PubMed ID: 29526921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Romidepsin Plus Liposomal Doxorubicin Is Safe and Effective in Patients with Relapsed or Refractory T-Cell Lymphoma: Results of a Phase I Dose-Escalation Study.
    Vu K; Wu CH; Yang CY; Zhan A; Cavallone E; Berry W; Heeter P; Pincus L; Wieduwilt MJ; William BM; Andreadis C; Kaplan LK; McCormick F; Porcu P; Brammer JE; Ai WZ
    Clin Cancer Res; 2020 Mar; 26(5):1000-1008. PubMed ID: 31772119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy.
    Coiffier B; Pro B; Prince HM; Foss F; Sokol L; Greenwood M; Caballero D; Borchmann P; Morschhauser F; Wilhelm M; Pinter-Brown L; Padmanabhan S; Shustov A; Nichols J; Carroll S; Balser J; Balser B; Horwitz S
    J Clin Oncol; 2012 Feb; 30(6):631-6. PubMed ID: 22271479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses.
    Coiffier B; Pro B; Prince HM; Foss F; Sokol L; Greenwood M; Caballero D; Morschhauser F; Wilhelm M; Pinter-Brown L; Padmanabhan Iyer S; Shustov A; Nielsen T; Nichols J; Wolfson J; Balser B; Horwitz S
    J Hematol Oncol; 2014 Jan; 7():11. PubMed ID: 24456586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Romidepsin for the Treatment of Peripheral T-Cell Lymphoma.
    Iyer SP; Foss FF
    Oncologist; 2015 Sep; 20(9):1084-91. PubMed ID: 26099743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients.
    Pellegrini C; Dodero A; Chiappella A; Monaco F; Degl'Innocenti D; Salvi F; Vitolo U; Argnani L; Corradini P; Zinzani PL;
    J Hematol Oncol; 2016 Apr; 9():38. PubMed ID: 27071522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Romidepsin: in the treatment of T-cell lymphoma.
    Yang LP
    Drugs; 2011 Jul; 71(11):1469-80. PubMed ID: 21812508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial.
    Foss F; Horwitz S; Pro B; Prince HM; Sokol L; Balser B; Wolfson J; Coiffier B
    J Hematol Oncol; 2016 Mar; 9():22. PubMed ID: 26965915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA).
    Bachy E; Camus V; Thieblemont C; Sibon D; Casasnovas RO; Ysebaert L; Damaj G; Guidez S; Pica GM; Kim WS; Lim ST; André M; García-Sancho AM; Penarrubia MJ; Staber PB; Trotman J; Hüttmann A; Stefoni V; Re A; Gaulard P; Delfau-Larue MH; de Leval L; Meignan M; Li J; Morschhauser F; Delarue R
    J Clin Oncol; 2022 Jan; 40(3):242-251. PubMed ID: 34843406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study.
    Falchi L; Ma H; Klein S; Lue JK; Montanari F; Marchi E; Deng C; Kim HA; Rada A; Jacob AT; Kinahan C; Francescone MM; Soderquist CR; Park DC; Bhagat G; Nandakumar R; Menezes D; Scotto L; Sokol L; Shustov AR; O'Connor OA
    Blood; 2021 Apr; 137(16):2161-2170. PubMed ID: 33171487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Responses to romidepsin by line of therapy in patients with relapsed or refractory peripheral T-cell lymphoma.
    Foss F; Pro B; Miles Prince H; Sokol L; Caballero D; Horwitz S; Coiffier B
    Cancer Med; 2017 Jan; 6(1):36-44. PubMed ID: 27981793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of tenalisib in combination with romidepsin in patients with relapsed/refractory T-cell lymphoma: results from a phase I/II open-label multicenter study.
    Iyer SP; Huen A; Ai WZ; Jagadeesh D; Lechowicz MJ; Okada C; Feldman TA; Ghione P; Alderuccio JP; Champion R; Kim SH; Mohrbacher A; Routhu KV; Barde P; Nair AM; Haverkos BM
    Haematologica; 2024 Jan; 109(1):209-219. PubMed ID: 37439343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Romidepsin for the treatment of T-cell lymphomas.
    McGraw AL
    Am J Health Syst Pharm; 2013 Jul; 70(13):1115-22. PubMed ID: 23784158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma.
    Amengual JE; Lichtenstein R; Lue J; Sawas A; Deng C; Lichtenstein E; Khan K; Atkins L; Rada A; Kim HA; Chiuzan C; Kalac M; Marchi E; Falchi L; Francescone MA; Schwartz L; Cremers S; O'Connor OA
    Blood; 2018 Jan; 131(4):397-407. PubMed ID: 29141948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphoma.
    Foss F; Coiffier B; Horwitz S; Pro B; Prince HM; Sokol L; Greenwood M; Lerner A; Caballero D; Baran E; Kim E; Nichols J; Balser B; Wolfson J; Whittaker S
    Biomark Res; 2014; 2():16. PubMed ID: 25279222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial.
    Damaj G; Gressin R; Bouabdallah K; Cartron G; Choufi B; Gyan E; Banos A; Jaccard A; Park S; Tournilhac O; Schiano-de Collela JM; Voillat L; Joly B; Le Gouill S; Saad A; Cony-Makhoul P; Vilque JP; Sanhes L; Schmidt-Tanguy A; Bubenheim M; Houot R; Diouf M; Marolleau JP; Béné MC; Martin A; Lamy T
    J Clin Oncol; 2013 Jan; 31(1):104-10. PubMed ID: 23109692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma.
    Piekarz RL; Frye R; Prince HM; Kirschbaum MH; Zain J; Allen SL; Jaffe ES; Ling A; Turner M; Peer CJ; Figg WD; Steinberg SM; Smith S; Joske D; Lewis I; Hutchins L; Craig M; Fojo AT; Wright JJ; Bates SE
    Blood; 2011 Jun; 117(22):5827-34. PubMed ID: 21355097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Romidepsin and lenalidomide-based regimens have efficacy in relapsed/refractory lymphoma: Combined analysis of two phase I studies with expansion cohorts.
    Mehta-Shah N; Lunning MA; Moskowitz AJ; Boruchov AM; Ruan J; Lynch P; Hamlin PA; Leonard J; Matasar MJ; Myskowski PL; Marzouk E; Nair S; Sholklapper T; Minnal V; Palomba ML; Vredenburgh J; Kumar A; Noy A; Straus DJ; Zelenetz AD; Schoder H; Rademaker J; Schaffer W; Galasso N; Ganesan N; Horwitz SM
    Am J Hematol; 2021 Oct; 96(10):1211-1222. PubMed ID: 34251048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.